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Metastatic colorectal cancer is often fatal, and drug resistance to chemotherapeutic agents is one 
of the primary contributing factors to this lethality.  Drug resistance arises from exposure to 
chemotherapies, and it can be mediated through a variety of mechanisms.  One of these 
mechanisms is alteration of enzymes within the cancer cells to affect the processing or removal 
of the drug.  Carboxylesterase is an example of an enzyme that converts irinotecan, a drug used 
in metastatic colorectal cancer treatments, into the active metabolite SN-38.  Carboxylesterase 
enzymes are found in high quantities in both the liver and intestinal cells.  The presence of 
carboxylesterase in intestinal and liver cells is an important consideration in the processing of 
colorectal cancer treatments.  Glutathione S-transferase is another enzyme that has been 
implicated in drug resistance because of its ability to conjugate reduced glutathione to xenobiotic 
substances, facilitating their removal.  Additionally, drug resistance can affect the behaviours of 
cells.  Drug-resistant cells can exhibit changes in their motility and aggressiveness compared to 
drug-sensitive cells.  In this study I investigated cellular behavioural changes in SN-38-resistant 
colon cancer cells compared to their SN-38-sensitive counterparts.  In addition to behavioural 
changes, I also sought to determine if elevations in carboxylesterase and glutathione S-
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Chapter 1. Introduction  
1.1 Colorectal Cancer Overview 
1.1.1 Colorectal cancer  
Colorectal cancer (CRC) is the third most common cancer in the world, and the second most 
common in Canada; affecting one in thirteen men and one in sixteen women (Cancer Stats 2017).  
CRC arises from normal cells after they accumulate a series of common mutations in important 
genes.  These mutations often result in altered oncogenes and loss of tumour suppressor gene 
function, contributing to the progression of CRC [1-3].  Some of the primary genes involved in 
this change are the adenomatous polyposis coli (APC) gene [4], K-ras mutation [2, 5], 
transforming growth factor β [6], and p53 [5, 7].  The alteration of these genes generally leads to 
a loss of function or control of cell cycling, which in turn allows cells to proliferate.  Some of the 
changes enable the cells to move beyond their normal growth checkpoints and boundaries that 








1.1.2 Common mutations in colorectal cancer   
The APC gene is considered a tumour suppressor gene, and its gene product prevents 
uncontrolled growth of cells.  An APC gene mutation can be congenital and result from an 
inherited mutation causing familial adenomatous polyposis.  This hereditary mutation 
predisposes people to CRC because they have a higher rate of polyp production compared to 
normal [8].  An APC mutation is often one of the first steps in a series of mutations that initiate 
CRC development [9].    
One of the most commonly mutated genes, found in roughly 40% of CRC cases, is a deleted or 
altered KRAS [2].  Many KRAS mutations result in constitutively active K-ras protein which 
maintains proliferation and survival signals.  Another protein that is often changed in CRC is 
p53.  p53 is a cellular checkpoint protein that prevents cells from continuing to grow and divide 
if they have excessive DNA damage.  p53 is also used by cells to shunt damaged cells towards 
programmed cell death, called apoptosis.  
1.1.3 Progression and stages of colorectal cancer 
As CRC tumour growth progresses through more layers of tissue, it is classified into stages 0 
through 4 (Figure 1).  The survival of a patient is closely tied to the stage of CRC they are 
diagnosed with.  Five-year survival rates are around 90% for localised, stage 1 CRC.  This high 
rate of survival is largely due to the successful resection of these tumours, removing the cancer.  
The five-year survival rates plummet to 12.5% for patients with metastatic disease [10].  Late 
stage cancer is challenging to treat; it is often resistant to chemotherapeutic drugs, and surgery is 







Figure 1 Stages 0 to 4 of colorectal cancer 
Progression of colorectal cancer from stage 0 to stage 4 with invasion of tissue layers.  Stage 0 is 
localised to the mucosa, stage 1 has penetrated the mucosa and submucosa.  Stage 2 has 
progressed into the remaining two layers of tissue – the muscularis and serosa.  Stage 3 CRC has 
migrated (yellow arrow) to nearby lymph nodes and stage 4 has spread to distant organs through 











Stage 0 CRC shows the preliminary signs of change and problems associated with the tissue.  In 
this stage, the cancer is localised and has not grown beyond the mucosa, the innermost layer of 
the colon.  This is referred to as a carcinoma in situ.  In stage 1 CRC, the cancer has grown into 
the submucosa – the connective tissue layer surrounding the mucosa.  Stage 2 CRC is 
characterised by the carcinoma having grown into the next layers of tissue, the muscularis and 
serosa.  In order to progress to Stage 3, the carcinoma must spread to local lymph nodes in the 
rectum and colon [11]. 
Stage 4 CRC has spread to distant organs in the body, a process called metastasis.  Cancer 
metastasis occurs when the carcinoma breaks beyond its normal boundaries and away from the 
basement membrane; the cancerous cells lose their attachments to the extracellular matrix (ECM) 
and spread to surrounding tissues.  Common sites of CRC metastasis are the liver, lungs, and 
brain.  The liver and intestines are connected through the portal vein, which acts as a direct shunt 
to the liver.  This physical connection contributes to the high levels of liver metastases from 
CRC [12].  In addition to this physical shunt, the liver likely has an appropriate niche 
microenvironment to attract and host circulating CRC cells [13, 14].  
In order for the cancer to progress in metastasis, the cells must undergo changes that promote 
motility, durability, and survival of the cell while losing its constraints that keep it at the 
basement membrane [15].  The combination of these alterations makes the epithelial cells 
resemble mesenchymal cells in morphology and behaviour.  These cellular changes are known as 
epithelial to mesenchymal transition (EMT).   
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1.2 Colorectal Cancer Treatments 
The treatment of CRC varies depending on the stage and aggression of the disease.  Stage 0 CRC 
can be removed using routine procedures, such as a colonoscopy, to perform a polypectomy.  
Typically, localised stage 1 cancer is resected along with a piece of the bowel and several nearby 
lymph nodes [11].  For stages 2 and 3, surgery is still considered the primary treatment for colon 
cancer.  Adjuvant chemotherapy may be introduced for stage 2 colon cancer patients following 
surgery, but it is commonly given to stage 3 cancer patients.  The chemotherapy drugs used often 
include a regimen of 5-fluorouracil (5-FU; Figure 2A), capecitabine, leucovorin, and oxaliplatin 
(Figure 2B) in various combinations [11, 16].  Irinotecan (Figure 2C) is introduced as a stage 4 
metastatic cancer treatment and in cases of recurrent CRC.  The most common combination of 
drugs in this late-stage scenario is FOLFIRI, which consists of leucovorin, 5-FU, and irinotecan 
[11].  
The cytotoxic effects of these drugs are mediated through a variety of mechanisms. 5-FU – a 
primary component in most CRC chemotherapy treatments – is an analogue of uracil, and is 
transported and introduced into RNA much like uracil itself [17].  Through the integration into 
RNA, 5-FU and its metabolites disrupt RNA processes.  5-FU also functions as a thymidylate 
synthase inhibitor [17], and prevents the synthesis of deoxythymidine monophosphate which 
then results in lower deoxythymidine triphosphate levels downstream.  The reduction in 
thymidine generation has detrimental effects on DNA replication because thymidine is an 
important deoxynucleotide; the ensuing imbalance in deoxynucleotides within the cells 























Figure 2 Structures of chemotherapy drugs 
Structures and molecular weights of the chemotherapy drugs 5-fluorouracil (A), oxaliplatin (B), 









Irinotecan is reserved for advanced stage and metastatic cancer; it is a topoisomerase 1 inhibitor.  
This inhibition is believed to occur through the stabilisation of topoisomerase 1-DNA 
intermediates known as cleavable complexes.  This stabilisation and inhibition of topoisomerase 
1 prevents the DNA strand breaks formed during replication from being repaired.  As a result, 




















1.3 Drug Metabolism  
Many drugs are administered in a pro-drug form that must be metabolised into active 
metabolites.  Irinotecan is a pro-drug that requires carboxylesterase (CES) enzymes to convert it 
into the active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) [20].  Activation of 
irinotecan occurs via a hydrolysis reaction involving CES cleavage of an acetate group from 
irinotecan, generating the SN-38 metabolite.  Inactivation of SN-38 primarily occurs through a 
glucuronidation reaction in which glucuronic acid is conjugated to SN-38, transforming it into 
SN-38 glucuronide (SN-38G).  SN-38G is secreted into bile for excretion [21].  Irinotecan is 
administered intravenously and is metabolised into its more potent active metabolite SN-38 
mainly in the liver (Figure 3).  The cytochrome P450 (CYP) enzyme family has prominent 
involvement in drug metabolism.  CYP 3A4 converts irinotecan into inactive metabolites 
through oxidation reactions.    
Irinotecan and SN-38 exist in inactive carboxylate and active lactone forms; this equilibrium is 
affected by pH and the presence of binding proteins [22, 23].  Lactone forms are more stable in 
the presence of albumin [24].  
Drugs that are orally administered must pass through a variety of pH environments, and must 
also be able to be absorbed through the gut and into the bloodstream [25], transport of the drug to 





Figure 3 Metabolic pathway of irinotecan in the liver 
Irinotecan is converted into the active metabolite SN-38 by carboxylesterase (CES) enzymes.  
SN-38 is inactivated by UDP glucuronosyltransferase (UGT) 1A1/7 enzymes, forming SN-38G.  
Irinotecan can be directly inactivated by cytochrome P450 3A4 (CYP 3A4) enzymes through an 








1.4 Drug Resistance in Colorectal Cancer 
1.4.1 Overview of drug resistance  
There are two main types of drug resistance, intrinsic and acquired.  Intrinsic resistance exists 
within the cancer prior to any treatments being administered.  Acquired drug resistance occurs 
over the course of successive chemotherapy treatments, and is commonly found in metastatic and 
recurrent disease.  Nearly all recurrent CRC has some form of drug resistance [26, 27].  Cells 
that are drug resistant are often multi-drug resistant, in which the cancer is resistant to many of 












1.4.2 Heterogeneity of cancer and drug resistance 
Drug resistance often arises over the course of successive chemotherapy treatments.  Metastatic 
CRC [28] and recurrent cancers are often drug resistant because they have had exposure to 
successive treatments of chemotherapies.  This exposure to a cytotoxic assault puts selective 
pressure on the cancer cells and eliminates cells unable to cope with the assault.  The cells react 
to the flux in selective pressure by adapting to their environments and altering how they process 
or remove compounds [26].  These adaptations can result in drug resistance [29] through a 
variety of mechanisms, as indicated in Figure 4.  Cells that have mechanisms to survive can then 
flourish.   
The heterogeneity of cancer cells encourages the acquisition of resistance mechanisms and 
aggressive traits in the cancer [30].  The cells most able to survive the changing conditions and 
rigors of movement through the body are the ones that grow and repopulate.  These resistance 
and genetic profiles of the cancer cells can change with treatments as the cells adapt to the new 
selective pressures they are exposed to.  This adaptation has been observed in liver metastases 










Figure 4 Mechanisms of drug resistance in cells  
Potential drug resistance mechanisms that cells can employ to reduce the presence and activity of 
chemotherapies within the cell.  Cells can decrease drug uptake (i) or increase efflux (ii) to 
reduce intracellular concentrations of the drug.  The metabolism of the drug may be altered (iii) 
through decreasing activation, or increasing deactivation to render the drug inactive.  Drug 
targets can be changed (iv) so the drugs cannot bind or act properly, limiting the cellular 
response to the drug.  Repair of DNA can be increased (v) which limits apoptotic pathway 













1.4.3 Altered cell cycle checkpoints and repair mechanisms 
Somatic cells have repair mechanisms to fix damaged DNA and remove aberrant proteins.  If 
these repair mechanisms fail, there are checkpoints within the cell cycle to prevent progression 
until the problem is fixed.  When the damage is too great, the cells may be triggered into 
apoptosis in order to eliminate the damaged and defective cells.  In many cancers, these repair 
functions and checkpoints are often bypassed or hijacked, allowing cells to grow and proliferate 
without hindrance.  An example of altered checkpoints would be the earlier stated mutations in 
p53 [7].   
1.4.4 Alteration of drug targets and metabolic changes in drug resistance 
The alteration of drug targets and enzymes involved in the metabolic pathways of the drugs can 
promote drug resistance in cells (Figure 4).  Cells can lower the levels of active metabolites of 
drugs within the cells, and can do so through changes in the metabolism of drugs and their 
metabolites.  These changes can be an increase deactivation or decrease activation, both of which 
would result in lower levels of the active metabolites being present within cells [32].  The 
metabolic state can also affect drug resistance in cells.  A particular example of this was in lung 
cancer cell lines that had high levels of mitochondrial reactive oxygen species following 
prolonged treatment with gefitinib.  These lung cancer cells exhibited EMT phenotypes until the 
withdrawal of gefitinib, which then led to lower levels of reactive oxygen species and a return to 





1.4.5 Cell signalling changes in drug resistance 
Alterations in cell signalling pathways are often present in cancers.  The mitogen-activated 
protein kinase (MAPK)/extracellular signal-regulated kinases (ERK) pathway is implicated in 
many different cancers [34] and CRC in particular [2].  This pathway can engender 
carcinogenesis as well as mediate drug resistance mechanisms [35].  A cell can also decrease its 
response to apoptotic signals, or increase cell survival signals.  These signalling changes can be 
accomplished by affecting the signalling molecules found within the pathways.  For example, c-
Jun N-terminal kinase (JNK) apoptotic signalling involves the activation of JNK1, which 
initiates a further signalling cascade involving pro-apoptotic Bcl-2 family proteins and caspases 
to stimulate cell death.  An example of drug resistance involving anti-apoptotic proteins from the 
Bcl-2 family was demonstrated in HCT116 cells that had drug resistance mediated through 
overexpression of Bcl-2 family proteins, thereby decreasing apoptotic signalling and resulting in 
cell survival [36].  
1.4.6 Altered uptake and efflux of compounds in drug-resistant cancer 
Alteration of cellular excretion of unwanted compounds plays a major role in drug resistance; a 
cell is more likely to survive if it is capable of removing cytotoxic compounds.  ATP-binding 
cassette (ABC) transporters actively use the catabolism of ATP to power the removal of 
substances from cells, and are often involved in multi-drug resistance [37].  P-glycoprotein (P-
gp) is a prime example of this function of ABC transporters.  P-gp is a promiscuous pump that 
has many interactions and the ability to remove a variety of substances and xenobiotics from the 
cell [38].  Increased activity of efflux pumps within cells is a large contributor to some forms of 
drug resistance [39].  
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1.5 Altered Behaviours of Drug-Resistant Cells 
Drug-resistant cells often display altered aggressiveness, motility, and invasive properties [40].  
Resistant cells can exhibit elongated fibroblast-like shapes, reminiscent of a mesenchymal 
phenotype [41].  Mesenchymal markers such as vimentin and the transcription factor Snail are 
often present in drug-resistant phenotypes [41, 42].   
These alterations in morphology and cellular markers indicate that those drug-resistant cancers 
are exhibiting signs of EMT, which in turn promotes motility and survival within the body and 
outside the normal bounds of the tissue [43, 44].  The transformation from epithelial 
characteristics to mesenchymal is also indicative of progression to a stem-cell like state.  The 
EMT and stem-cell like properties relate to chemoresistance [42, 45], once again implicating 
drug resistance in metastatic cancers.  Eventually, once these cells have metastasised and 
travelled to alternate locations in the body, they will undergo the reverse process – known as 
mesenchymal to epithelial transition (MET) – which will enable the cancer to grow and 








1.6 Cell Adhesion 
Adhesion of cells to the ECM by cell membrane proteins, such as integrins, can elicit 
intracellular signalling cascades.  In this way, cellular adhesion to the ECM can be involved in 
drug resistance through altered signalling pathways being initiated by the adhesion events [46].  
Metastatic and drug-resistant cancers can be better at navigating the ECM.  In order to facilitate 
movement through the ECM, cells must degrade some components in order to clear a pathway to 
travel through.  
Cell adhesion is mediated by a multitude of proteins and structures.  One of the primary 
components of the ECM is fibronectin (FN).  FN provides not only structural elements to the 
ECM, but it also gives anchoring points for cells to the ECM [47].  Additionally, this cellular 
anchoring to FN is involved in signalling activities [46].  This signalling occurs through a variety 
of pathways, primarily through integrins.  Integrins bind to FN in a ligand-receptor manner with 
the arginine-glycine-aspartic acid (RGD) sequence on fibronectin being the ligand and the 
integrin the receptor.  The RGD motif has been shown to play a role in cancer metastasis, 
particularly the EMT and MET changes that cells undergo [48, 49].  Cellular adhesion can 
mediate drug resistance in cancer [50, 51]. 
Matrix metalloproteinases (MMPs) are proteins that cells use to facilitate ECM degradation.  In 
some cases, drug-resistant and metastatic cancers have elevated MMPs [52], and the inhibition of 
these MMPs could potentially improve treatment of drug-resistant cancers, such as in ovarian 




Carboxylesterase enzymes (CES) are ubiquitously distributed throughout the body.  There are 
two main forms; carboxylesterase 1 (CES1), found primarily within the liver, and 
carboxylesterase 2 (CES2), which is located in the intestinal cells [54].  CES2 located on the 
external cell membranes can catalyse extracellular reactions and CES2 present within the cells 
contributes to intracellular metabolism.  
CES metabolises irinotecan and converts it into the active metabolite SN-38.  The primary site of 
activation is in the liver – where CES1 is abundant – because irinotecan is administered as an 
intravenous infusion.  Irinotecan is not in direct contact with the lumen of the intestines, 
diminishing the role of CES2 in the initial metabolism.  Irinotecan that passes through the liver 
and is not converted can potentially be converted by intestinal cells as they are supplied with 
blood.  CES2 exhibits a higher rate of hydrolysis than CES1 [55], which is likely related to the 
broader substrate specificity of CES1 [56].  
CES can be inhibited by loperamide, a drug used to stop symptomatic diarrhea that occurs as a 
result of treatment with irinotecan.  Although inhibition of the enzyme responsible for the 
metabolism of irinotecan into SN-38 seems counter-intuitive as a clinical strategy, there is not a 
significant decrease in the therapeutic effectiveness of irinotecan when treating diarrhea 
symptoms with loperamide [57].  Additionally, loperamide likely has a greater effect on CES2 
due to low bioavailability and its primary action on enzymes within the gut.  Loperamide is, 
however, metabolised by CYP enzymes in the liver [58]. 
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1.8 Glutathione S-Transferase 
Glutathione S-transferase (GST) is an enzyme that conjugates reduced glutathione (GSH) to 
xenobiotics to facilitate their removal; these substances are then secreted into bile for excretion. 
GST is also involved in inflammatory responses, which is important considering the 
inflammatory nature of cancer as a disease.   
There are several isoforms of GST.  The isoform that is largely responsible for drug inactivation 
and removal in humans is GST pi (GSTP).  In particular, GSTP1-1 removes drugs from the body 
and inactivates compounds.  GSTP has elevated expression in proliferating cells [59].  In 
addition to this, GSTP is implicated in several cancers and drug-resistance mechanisms [60].  
GST can be upregulated when cells are exposed to anticancer drugs, including irinotecan.  In a 
study from 2002, partial sensitivity to irinotecan was returned to cells following treatment with a 
GSTP inhibitor [60].  
GST is also relevant to MAPK pathways, which are important in signalling cascades.  Cytosolic 
GST plays a role of inhibition in MAPK pathways, and acts on cell signalling molecules for 
survival and inhibition of cell death.  This could mean that rather than detoxification of cells, 
GST may be involved in alteration of survival and apoptotic signalling [61].  Of note, GSTP1 
binds to JNK; this binding inhibits the downstream apoptotic signalling elicited by JNK1 [62].  
When it is unbound to GSTP1, JNK normally signals the Bcl-2-family protein Bax, which has 
further downstream signals that result in the promotion of apoptosis.  
GSTP exists in both a monomeric and a dimeric state.  When in the dimeric configuration, GSTP 
functions primarily to clear xenobiotics from the cells [62].  In the monomeric state, GSTP has 
been shown to form protein complexes with JNK, in particular with JNK1 [62].  
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1.9 Rationale for the Project 
Drug resistance in CRC heavily contributes towards the poor outcomes in patients.  Considering 
the lethality of metastatic and drug-resistant CRC, it is important to gain a greater understanding 
of how metastatic and drug-resistant CRC differ from drug-sensitive and localised CRC.  The 
aim of this project was to study these differences and elucidate some of the cellular behavioural 
and enzymatic changes that contribute to these alterations in patient outcomes.  GST was chosen 
as an enzyme of importance to study due to its implication in drug resistance.  CES enzymes 
were selected for their involvement in both drug resistance and irinotecan metabolism.  Through 













1.10 Hypothesis and Objectives 
Hypothesis  
Drug resistance in colorectal cancer confers increased adhesion, and is promoted by the presence 
and activity of the metabolic enzymes carboxylesterase and glutathione S-transferase. 
 
The objectives of my project were to identify and quantify changes in: 
1. Adhesion of HT29 and SN-38-resistant HT29-S colon carcinoma cells on a fibronectin 
substratum and a HepG2 hepatocellular carcinoma monolayer 
2. 5-chloromethylfluorescein diacetate conversion between SN-38-sensitive and SN-38-
resistant colon carcinoma cells 
3. Carboxylesterase activity in SN-38-sensitive and SN-38-resistant colon carcinoma cells  








Chapter 2. Methods  
2.1 Cell Culture  
The six cell lines listed in Table 1 were cultured for this study.  The cell lines HT29, HCT116, 
Caco-2, and HepG2 were obtained from American Type Culture Collection (Manassas, VA, 
United States).  The HT29-S and HCT116-S cell lines were established by Dr. Murray Cutler 
through successive treatment of HT29 and HCT116 cells with low levels of SN-38 (Sigma 
Aldrich) increased to a concentration of 30 nM SN-38, and were resistant to cytotoxicity by SN-
38.  HT29-S and HCT116-S were cultured with 30 nM of SN-38 to maintain the drug-resistant 
phenotype.  All cell lines were cultured using Dulbecco’s modified Eagle’s medium (DMEM; 
HyCLone Laboratories Inc.) with additional additives to the media such as new-born calf serum 
(NCS; ThermoFisher Scientific) and fetal bovine serum (FBS; VWR International).  
Table 1 Cell lines and cell culture components 
Cell Line Media Additions 
HT29 5% FBS,10% NCS  
HT29-S 5% FBS, 10% NCS 30 nM SN-38 
HCT116 10% NCS  
HCT116-S 10% NCS 30 nM SN-38 
Caco-2 5% FBS  






2.2 Staining Cells with 5-chloromethylfluorescein diacetate (CMFDA) 
The six cell lines were cultured in T25 flasks (Nunc™) and grown to 80-90% confluence.  The 
media were aspirated off and cells released using 1 mL of 0.25% trypsin-
ethylenediaminetetraacetic acid (EDTA; Gibco™) followed by incubation at 37 °C for 10-15 
min.  To inactivate the trypsin-EDTA, the cells were suspended in 5 mL of DMEM 10% FBS for 
the HT29-S, HepG2, and Caco-2 cells, and 10% NCS for the HT29, HCT116, and HCT116-S 
cells.  The cells were centrifuged using an Allegra X-22R Centrifuge (Beckman Coulter) at 400 x 
g for 3 min at 4 °C and the supernatant removed.  The cells were suspended in serum-free 
DMEM to a concentration of 50 000 cells/mL; 5 µL/mL of 5-chloromethylfluorescein diacetate 
(CMFDA) was added and the cell suspensions incubated at 37 °C for 30 min to stain.  Cells were 
centrifuged again at 400 x g at 4 °C for 3 min.  The supernatant was removed and the cells 
suspended in 10% FBS, then incubated for a further 30 min at 37 °C to wash away excess 
CMFDA.  Cells were centrifuged for a final time at 400 x g for 3 min at 4 °C, then suspended in 
DMEM with or without FBS or NCS according to the conditions necessary for each experiment 






2.3 Cell Adhesion Assays 
2.3.1 Cell adhesion assays on glass coverslips 
Glass coverslips that were 22 mm in diameter (ThermoFisher Scientific) were placed in 24-well 
plates and coated with 300 μL of 100 μg/mL Poly-L-lysine (PLL; Sigma Aldrich) in MilliQ H2O 
and incubated at 37 °C for 10 min.  Excess PLL solution was removed and the coverslips 
allowed to dry at room temperature. Cell suspensions were stained using CMFDA.  50 000 cells, 
stained with CMFDA, in 500 μL were added onto the coverslips and incubated at 37 °C for 2.5 h 
for adhesion.  Following the adhesion period, coverslips were gently washed with phosphate 
buffered saline (PBS) to remove any cells that were unadhered.  The coverslips were mounted on 
glass slides using a drop Fluoroshield aqueous gel mountant containing 1 μg/mL 2-(4-
amidinophenyl)-1H-indole-6-carboxamidine (DAPI; Abcam). Slides were protected from the 
light and dried overnight at room temperature.  Fluorescence was detected using a Leica 
DM2000 light microscope.  Images were taken using a QImaging Micropublisher 5.0 RTV 








2.3.2 Cell adhesion on a fibronectin substratum 
4-well plates were coated with 500 μL of 5 μg/mL bovine plasma fibronectin (Sigma Aldrich) in 
MilliQ H2O overnight at 4 °C.  The remaining fibronectin solution was removed the following 
day and 500 μL of 2% bovine serum albumin (BSA; Sigma Aldrich) in serum-free DMEM was 
applied for 10 min at room temperature as a blocking solution.  HT29 and HT29-S cells were 
released from their T25 flasks using 1 mL of TrypLE Express enzyme (Life Technologies) and 
suspended in 4 mL of DMEM 10% FBS to inactivate the TrypLE enzyme.  Cells were collected 
and centrifuged using an Allegra X-22R Centrifuge (Beckman Coulter) at 400 x g for 3 min at 4 
°C.  The supernatant was discarded and the cells suspended in 5 mL of cold PBS to wash away 
remaining serum.  The cells were centrifuged at 400 x g for 3 min at 4 °C, and the supernatant 
discarded; the cells were suspended in 5 mL of serum-free DMEM and counted using a 
Multisizer 4 Coulter Counter (Beckman Coulter) to determine the concentration of this 
suspension.  The cells were diluted to a concentration of 100 000 cells/mL and stained with 
CMFDA.  500 μL of the cell suspension was added to each well of the fibronectin coated 4-well 
plates and the plates incubated at 37 °C for 2.5 h to allow for adhesion.  Following the adhesion 
period, coverslips were gently washed with PBS to remove any unadhered cells.  Fluorescence 
was detected using a Leica DM2000 light microscope.  Images were taken using a QImaging 





2.3.3 Cell adhesion on a HepG2 hepatocellular carcinoma monolayer 
4-well plates were seeded with 500 μL of a HepG2 cell suspension, and incubated at 37 °C, 5% 
CO2 until the HepG2 cells were approximately 90% confluent.  After the HepG2 monolayer was 
grown, the medium was removed and the wells washed using PBS.  300 μL of 3.7% 
paraformaldehyde (PFA; Sigma Aldrich) was used to fix the HepG2 cells in a control well.  
HT29 and HT29-S cells were released from their T25 flasks using 1 mL of TrypLE Express 
enzyme (Life Technologies) and suspended in 4 mL of DMEM 10% FBS to inactivate the 
TrypLE enzyme.  Cells were collected and centrifuged using an Allegra X-22R Centrifuge 
(Beckman Coulter) at 400 x g for 3 min at 4 °C.  The supernatant was discarded and the cells 
suspended in 5 mL of cold PBS to wash away remaining serum; the cells were centrifuged again 
at 400 x g for 3 min at 4 °C.  The supernatant was discarded and the cells were suspended in 5 
mL of serum-free DMEM and counted using a Multisizer 4 Coulter Counter (Beckman Coulter) 
to determine the concentration of the suspension.  The cells were stained with CMFDA. 50 000 
cells, stained with CMFDA, in 500 μL were added to each well of the 4-well plates and the 
plates were incubated at 37 °C for 2.5 h to allow for adhesion.  Following the adhesion period, 
the wells were gently washed with PBS to remove any unadhered cells.  Fluorescence was 
detected using a Leica DM2000 light microscope and images were captured using a QImaging 





2.4 5-chloromethylfluorescein diacetate (CMFDA) Conversion Experiment  
The six cell lines were cultured in T75 flasks (Nunc™) and grown to 80-90% confluence. The 
media were aspirated off and cells released using 3 mL of 0.25% trypsin-EDTA (Gibco™) 
followed by incubation at 37 °C for 10-15 min.  To inactivate the trypsin-EDTA, the cells were 
suspended in 5 mL of DMEM 10% FBS for the HT29-S, HepG2, and Caco-2 cells, and 10% 
NCS for the HT29, HCT116, and HCT116-S cells.  The cells were counted using a Multisizer 4 
Coulter Counter (Beckman Coulter) and separated at 1 x 106 cells per tube into 1.5 mL 
Eppendorf tubes. The cells were stained using CMFDA with an adjusted protocol involving 
extended incubation periods – a 1 h stain period followed by a 30 min wash out period. 
Unstained cells were used as controls.  The cells were centrifuged using a 5424R 
microcentrifuge (Eppendorf) at 400 x g for 10 min at 4 °C.  Supernatant was removed using 
gentle aspiration.  The lysis buffer (A.1.3 Lysis Buffer) was added to the cells and the tubes were 
agitated intermittently for approximately 30 min until the cells were lysed and well 
homogenised.  The lysate was centrifuged at 14 000 x g for 5 min at 4 °C using a 5424R 
microcentrifuge (Eppendorf).  200 μL of the supernatant was transferred into a 96-well plate. 
Fluorescence levels were measured using a spectrofluorometer (SpectraMax M5) and excitation 





2.5 Carboxylesterase Activity Assays 
2.5.1 4-methylumbelliferyl acetate (4-MUBA) conversion 
HT29, HT29-S, HCT116, HCT116-S, HepG2, and Caco-2 cells were cultured in 24-well plates 
using eight wells per cell line, and grown to 80-90% confluence.  The media were removed and 
cells were released from four wells per cell line using 200 μL of 0.25% trypsin-EDTA and 
incubated at 37 °C, 5% CO2 for 10-15 min.  The released cells were counted using the Multisizer 
4 Coulter Counter (Beckman Coulter).  100 μL of lysis buffer was added to the remaining wells 
and the plate was placed at 4 °C for 10 min.  The plates were agitated and the lysates from each 
well collected and transferred into individual 1.5 mL Eppendorf tubes, using 1 tube per well.  
The lysates were separated using a 5424R microcentrifuge (Eppendorf) at 14 000 x g for 10 min 
at 4 °C.  A 96-well plate was prepared and 120 μL of a 0.083 mM 4-methyumbelliferyl acetate 
(4-MUBA; Alfa Aesar) substrate solution in KPBS Ca2+ Mg2+ (Appendix A.1.4 Phosphate 
Buffer with Ca2+ Mg2+) was added to the respective wells – four wells per cell line plus an 
additional four wells for blanks.  80 μL of supernatant from the centrifuged tubes was added to 
the 4-MUBA filled wells, and the solutions gently mixed.  80 μL of the lysis buffer was added to 
the blank wells.  Fluorescence readings were measured at 10 min intervals over a 3 h period 
(Figure 5) at room temperature using a SpectraMax spectrofluorometer (Molecular Devices) set 
to 350 nm emission and 450 nm excitation parameters.  The results were normalised by 
subtracting the blank values, then adjusting the resulting values to cell counts obtained from the 
four wells of each cell line.  A fixed assay time of 2.5 h was chosen based on the results found in 





Figure 5 Time course of carboxylesterase activity in colon cancer cells using 4-
methylumbelliferyl acetate 
HT29 and HT29-S (A), HCT116 and HCT116-S (B), and Caco-2 (C) cells were grown to 90% 
confluence.  The cells were counted and lysed.  80 µL of lysate was placed in a 96-well plate, 
and 120 µL of 0.083 mM 4-methyumbelliferyl acetate substrate added to reach a final 
concentration of 0.05 mM.  The data are mean relative fluorescence units ± SEM of three 
technical replicates plotted over a 3 h time course with readings taken every 10 min.  The blank 







Solutions used in the 4-MUBA assays showed some fluorescence (Figure 6), but this was 
determined to be of little interference in the 4-MUBA assays themselves when using blank 
control wells of the solutions. There were higher fluorescence readings from the black plates for 
most of the solutions used except KPBS Ca2+ Mg2+.  These results indicated that the clear plates 










Figure 6 Fluorescence of clear and black 96-well plates and solutions used in 4-
methylumbelliferyl acetate experiments  
Black and clear plates were selected to compare potential fluorescent interference between wells.  
The solutions used in the 4-methylumbelliferyl acetate assays were assessed for their potential 
fluorescence.  Panels A and B are experimental replicates.  The data are means are of three 









2.5.2 p-nitrophenyl acetate (pNP) conversion 
24-well plates were seeded with HT29, HT29-S, HCT116, HCT116-S, HepG2, and Caco-2 using 
eight wells per cell line, 500 µL per well.  The cells were grown to 80-90% confluent.  The 
media were aspirated from the wells, and the cells released from four wells per cell line using 
200 μL of 0.25% trypsin-EDTA and incubation at 37 °C, 10% CO2 for 10-15 min.  The cells 
were counted using the Multisizer 4 Coulter Counter (Beckman Coulter) and a Modified 
Neubauer hemocytometer.  A solution of 2 mM p-nitrophenyl acetate (pNP) in 50 mM trisHCL 
buffer (pH 7.0) was prepared.  The 24-well plates were washed twice using 500 µL of cold PBS 
per well.  The PBS was gently aspirated and 250 µL of the pNP solution was added to each of 
the four remaining wells.   The plates were incubated at 37 °C, 10% CO2 for 2 h.  A plate with 2 
mM pNP solution was kept in the same conditions as the plates containing cells and served as a 
blank.  50 µL of supernatant was removed and transferred to a 96-well plate at 20 min, 40 min, 
and 120 min intervals over the incubation period.  Absorbance values were measured at a 405 
nm wavelength using the SpectraMax spectrophotometer (Molecular Devices).  These values 
were normalised to the cell counts acquired for each cell line following subtraction of the blank 
values (Figure 7).  After the initial optimisation experiments, HepG2 cells were deemed 




Figure 7 Cytotoxicity of 2.0 mM p-nitrophenyl acetate in different colon cancer cells 
50 000 cells were added to 24-well plates and grown to 90% confluence.  Half of the wells were 
treated with the 2.0 mM p-nitrophenyl (pNP) acetate solution and the other half untreated.  The 
pNP treated wells display high levels of cytotoxicity to cells after an exposure of 2 h.  Data 
presented are means ± SEM of three technical replicates normalised to cell counts.  Blank values 











Following the initial pNP assay, six concentrations of pNP were used. HT29, HT29-S, HCT116, 
HCT116-S, and Caco-2 cells were cultured in 24-well plates, one plate per cell line, and grown 
to 80-90% confluence.  The media were aspirated from the wells, and cells were released from 
six wells of each cell line by using 200 μL of 0.25% trypsin-EDTA and incubation at 37 °C, 10% 
CO2 for 10-15 min.  The cells were counted using a Multisizer 4 Coulter Counter (Beckman 
Coulter) and a Modified Neubauer hemocytometer.  The media were aspirated from the 
remaining wells and the cells washed twice with 500 μL of cold PBS. 250 μL of pNP in 50 mM 
trisHCl buffer (pH 7.0) was added to the wells.  The plates were incubated for 2 h at 37 °C, 10% 
CO2.  A 24-well plate with wells filled with each of the six concentrations of pNP was incubated 
in the same conditions to serve as the blanks.  50 μL of supernatant was transferred from each 
well to a 96-well plate at 20 min, 40 min, and 120 min time intervals during the incubation 
period (Figure 8).  Absorbance values were measured at a 405 nm wavelength using the 
SpectraMax spectrophotometer (Molecular Devices).  The acquired absorbance values were 
normalised by subtracting the blanks and adjusting the resulting values to the cell counts for each 
cell line.  
Based on the data acquired in Figure 8, it was determined that 40 min was the optimal time 
interval to use.  This was supported by the decrease in activity at 120 min, which is likely 





Figure 8 Conversion of p-nitrophenyl acetate in different colon cancer cells  
Cells were grown to approximately 90% confluence in 24-well plates.  Six concentrations of p-
nitrophenyl acetate were added and the cells incubated at 37 °C, 5% CO2.  Supernatant was 
removed at 20 min (A), 40 min (B), and 120 min (C) time intervals and absorbance measured at 
405 nm.  Blank values were subtracted from absorbances and the resulting values adjusted to cell 






2.6 Glutathione S-Transferase Activity Assay 
HT29, HT29-S, HCT116, HCT116-S, and Caco-2 cells were cultured in 24-well plates using 
twelve wells per cell line, and grown to 80-90% confluence.  The media were aspirated from the 
wells and cells released using 200 μL of 0.25% trypsin-EDTA and incubation at 37 °C, 10% CO2 
for 10-15 min.  The cells were counted from six wells per cell line using a Multisizer 4 Coulter 
Counter (Beckman Coulter) and a Modified Neubauer hemocytometer.  The contents of the 
remaining six wells were suspended in separate 1.5 mL Eppendorf tubes, one tube per well.  The 
cells were centrifuged at 500 x g for 10 min at 4 °C using a 5424R microcentrifuge (Eppendorf).  
The supernatant was gently removed and the pelleted cells suspended in 80 μL of lysis buffer 
and agitated intermittently for 20-30 min until homogenised.  The contents of the tubes were 
centrifuged at 14 000 x g for 5 min at 4 °C using a 5424R microcentrifuge (Eppendorf).  20 μL 
of supernatant was transferred to a 96-well plate prepared using 1 mM 1-chloro-2,4-
dinitrobenzene (CDNB) and 2 mM reduced glutathione (GSH) as substrates, see Table 2 for the 
preparation of the 96-well plate.  The reaction time was 10 min at room temperature with 
absorbance values measured at 2 min intervals (Figure 9), a fixed endpoint of 10 min was used 
for further GST activity assays.  Absorbance values were measured at 340 nm using the 
SpectraMax spectrophotometer (Molecular Devices) and normalised by subtracting the blanks 






Table 2  Solution volumes for glutathione S-transferase activity experiments using 1 mM 1-
chloro-2,4-dinitrobenzene (CDNB) and 2 mM reduced glutathione (GSH) 
Label  Supernatant  CDNB + GSH 
Substrate  
Lysis buffer  Number of 
wells  
HT29  20 μL  180 μL  0 μL  6  
HT29-S  20 μL  180 μL  0 μL  6  
HCT116  20 μL  180 μL  0 μL  6  
HCT116-S  20 μL  180 μL  0 μL  6  
Caco-2  20 μL  180 μL  0 μL  6  
Substrate Blank  0 μL  180 μL  20 μL  6  




Figure 9 Glutathione S-transferase activity in different colon cancer cells 
Time course evaluation of glutathione S-transferase activity using cell lysates from HT29 (A,B), 
HT29-S (B), HCT116 (A,C), HCT116-S (C), and Caco-2 (A) cell lines.  1 mM of 1-chloro-2,4-
dinitobenzene and 2 mM reduced glutathione were used as substrates.  Absorbance readings 
were taken at a 340 nm wavelength every 2 min for 10 min.  Data are means presented ± SEM of 
three technical replicates normalised by subtracting blanks and adjusting the resulting values to 






HT29, HT29-S, HCT116, HCT116-S, HepG2, and Caco-2 cells were cultured in 24-well plates 
with twelve wells per cell line, and grown to 80-90% confluence.  The media were aspirated 
from the wells and the cells released using 200 μL of 0.25% trypsin-EDTA and incubation at 37 
°C, 10% CO2 for 10-15 min.  The cells from six wells per cell line were counted using a 
Multisizer 4 Coulter Counter (Beckman Coulter) and a Modified Neubauer hemocytometer.  The 
contents of the remaining six wells were suspended in separate 1.5 mL Eppendorf tubes, using 
one tube per well.  The cells were centrifuged at 500 x g for 10 min at 4 °C using a 5424R 
microcentrifuge (Eppendorf).  The supernatant was gently removed and the pelleted cells 
suspended in 80 μL of lysis buffer and agitated intermittently for 20-30 min until homogenised.  
The contents of the tubes were separated using a 5424R microcentrifuge (Eppendorf) at 14 000 x 
g for 5 min at 4 °C. 20 μL of the supernatant was transferred to a 96-well plate prepared using 
CDNB and GSH as substrates in a 1:2 ratio, see Table 3 for the 96-well plate set-up volumes.  
The reaction took place over the course of 10 min at room temperature.  Absorbance values were 
measured at 340 nm using the SpectraMax spectrophotometer (Molecular Devices) and 
absorbance values were normalised by subtracting the blanks and adjusting the resulting values 
to the cell counts for each cell line. 
Table 3 Solution volumes for glutathione S-transferase activity experiments using six 
concentrations of 1-chloro-2,4-dinitrobenzene (CDNB) and reduced glutathione (GSH)  
Label  Supernatant  CDNB + GSH 
Substrate  
Lysis buffer  Number of wells  
HT29  20 μL  180 μL  0 μL  3 per concentration 
HT29-S  20 μL  180 μL  0 μL  3 per concentration 
HCT116  20 μL  180 μL  0 μL  3 per concentration 
HCT116-S  20 μL  180 μL  0 μL  3 per concentration 
HepG2  20 μL  180 μL  0 μL  3 per concentration 
Caco-2  20 μL  180 μL  0 μL  3 per concentration 
Substrate Blank  0 μL  180 μL  20 μL  3 per concentration 




2.7 Statistical Analysis  
Experiments were performed with technical triplicate, and repeated as several independent 
experiments for biological replicates.  For quantitative measurements, results were reported as 
the mean ± standard error of the mean (SEM).  For non-quantitative experiments, the data 
selected and presented were representative of all the results.  One-way and two-way ANOVAs 
were used along with either Bonferroni or Dunnett’s multiple comparisons tests as appropriate. 
GraphPad Prism® software was used to perform data analysis.  
2.8 Generation of Figures  
Figure 1, Figure 3, Figure 4, Figure 17, and Figure 18 were adapted from Servier Medical Art by 









Chapter 3. Results  
3.1 Cell Adhesion 
3.1.1 Overview 
I wished to test the adhesion of the HT29 and SN-38-resistant HT29-S colon cancer cells, and to 
determine if the drug-resistant cells had a higher capacity for adhesion than the drug-sensitive 
cells.  The ability of these cells to adhere to fibronectin as a main component of the ECM was 
first assessed; following that, I wished to observe the interaction of the cells with a more 
complex ECM.  HepG2 hepatocellular carcinoma cells were used to provide a more complex 
ECM and functioned as a model liver environment, simulating the primary metastatic site of 
CRC.  
3.1.2 Adhesion of HT29 and SN-38-resistant HT29-S cells to fibronectin 
To assess the adhesion of drug-sensitive and drug-resistant cells to fibronectin, HT29 and HT29-
S cells were stained with CMFDA and added to fibronectin-coated wells.  After 2 h of incubation 
at 37 °C, the drug-sensitive cells had lower levels of adhesion compared to the drug-resistant 
cells.  This can be seen in Figure 10.  The HT29-S cells were also more heavily clustered, and 






Figure 10 Increased adhesion of SN-38-resistant HT29-S colon cancer cells to fibronectin  
HT29 (top) and HT29-S (bottom) adhered to wells coated with 500 µL of 5 µg/mL solubilised 
fibronectin.  50 000 cells, stained with CMFDA, in 500 µL of serum-free DMEM were added to 
the fibronectin coated wells.  The cells were allowed to adhere for 2.5 h at 37°C, 5% CO2.  The 





3.1.3 Adhesion of HT29 and SN-38-resistant HT29-S cells to HepG2 hepatocellular 
carcinoma cells 
Following these observations using FN, I wanted to assess the adhesion behaviours in a more 
complex ECM environment.  To accomplish this, monolayers of HepG2 hepatocellular 
carcinoma cells were grown in the wells.  A bright field image of the monolayer can be seen in 
Figure 11 along with the fluorescent image of adhered HT29 cells in the same field of view.  
CMFDA-stained HT29 and HT29-S cells were added to the wells and incubated at 37 °C for 2.5 
h.  Adhesion of the HT29 and HT29-S cells was observed using fluorescent microscopy.  The 
numbers of cells adhered were greater for both HT29 and HT29-S when compared to adhesion to 
the FN substratum.  This increase in adhesion is understandable given the multitude of other 
components the cells can adhere to within a fully established ECM.  There was a substantial 
increase in the adhesion of HT29-S cells compared to the HT29 cells (Figure 12).  Irregularity of 






Figure 11 HT29 colon cancer cells adhered to a HepG2 hepatocellular carcinoma 
monolayer  
Bright field (top) and fluorescent (bottom) images of HT29 cells bound to a HepG2 
hepatocellular carcinoma monolayer.  50 000 HT29 cells, stained with CMFDA, in 500 µL of 
serum-free DMEM were added to HepG2 monolayer coated wells in a 4-well plate at 37 °C, 5% 





Figure 12 Increased adhesion of SN-38-resistant HT29-S colon cancer cells on a HepG2 
hepatocellular carcinoma monolayer  
HT29 (top) and HT29-S (bottom) images of HT29 cells bound to a HepG2 hepatocellular 
carcinoma monolayer.  50 000 cells, stained with CMFDA, in 500 µL were added to the 
respective wells coated with a HepG2 monolayer, and allowed to adhere for 2.5 h at 37 °C, 5% 
CO2.  The plates were gently rinsed using ice-cold PBS and images taken using QCapture Pro.  
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3.2 5-chloromethylfluorescein diacetate (CMFDA) Conversion in Colon 
Cancer Cells  
During the cell adhesion experiments, I noticed on multiple occasions that the HT29-S SN-38-
resistant cells were a much more intense green colour than the HT29 cells.  This difference in 
intensity was clearly visible with the naked eye and was confirmed by colleagues within the lab.  
I wished to determine quantitatively whether or not the drug-resistant cell lines were being 
stained more intensely than the drug-sensitive ones.  This assessment was accomplished by 
measuring the fluorescence of CMFDA stained cells in a pilot experiment.  In this experiment, 
cells from each cell line were stained with CMFDA, and unstained cells were used for controls.  
Next, the cells were lysed to release their cellular contents and the fluorescence of the lysate 
solutions was measured.  HCT116 and SN-38-resistant HCT116-S colon cancer cells were 
included as a second pair of drug-sensitive and drug-resistant cell lines to observe potential 
patterns across the multiple cell lines.  Caco-2 colon cancer cells were included as a well-
differentiated colon cancer control cell line.  In observing the drug-sensitive lines, the Caco-2 
cells used for CRC controls had significantly higher relative fluorescence than the HT29 and 
HCT116 colon cancer cells (Figure 13A).  The HCT116 cells had lower levels of CMFDA 








Figure 13 5-chloromethylfluorescein diacetate (CMFDA) conversion in different colon 
cancer cells   
Relative fluorescence units of HT29 (A,B), HT29-S (B), HCT116 (A,C), HCT116-S (C), and 
Caco-2 (A).  Three replicates of 1x106 cells for each cell line were stained with 5 µL of 
CMFDA, and unstained cells were used as controls.  Following staining, the cells were lysed 
with 300 µL of lysis buffer and intermittently vortexed for 30 min.  After centrifugation, 200 µL 
of lysate supernatant was placed in a 96-well plate and the fluorescence was measured using 
excitation and emission wavelengths of 492 nm and 517 nm, respectively.  Data were analysed 
with a one-way ANOVA with Bonferroni multiple comparisons test. ***p<0.0001 shows a 
highly significant increase in CMFDA conversion between HT29-S SN-38-resistant cells and 
HT29 SN-38-sensitive cells.  ** p=0.0002 indicates a significant increase in CMFDA conversion 






Next, CMFDA conversion was compared in the SN-38-resistant cell lines HT29-S and HCT116-
S to their drug-sensitive counterparts.  In both pairs, the drug-resistant cells showed higher levels 
of CMFDA conversion than the drug-sensitive cells.  This difference was particularly notable in 
the HT29 and HT29-S pair as there was nearly a three-fold increase in CMFDA conversion in 
the HT29-S cells (p<0.0001), shown in Figure 13B.  The difference was less dramatic in the 
HCT116 and HCT116-S pair (p=0.0002), but the HCT116-S drug-resistant cells did show 
marginally elevated CMFDA conversion, as shown in Figure 13C.  The Caco-2 cell line 
exhibited extremely high levels of fluorescence, indicating extensive enzymatic conversion of 
the CMFDA.  These high levels are likely resulting from the highly differentiated nature of the 
Caco-2 colon cancer cells.  The fluorescent readings of all the unstained control cells were 
negligible. Once it was determined that there were indeed differences in the enzymatic 
conversion of CMFDA between the drug-resistant and drug-sensitive cell lines, further 









3.3.1 4-methylumbelliferyl acetate (4-MUBA) conversion in colon cancer cells  
The first assay chosen to assess CES activity was the conversion of 4-MUBA into the fluorescent 
product 4-methyumbelliferone.  Cells were grown and lysed to release their cellular contents.  
The supernatant from the lysate was placed in a 96-well plate and 4-MUBA added.  The 
fluorescence of the 4-MUBA and lysate mixes was measured after 2.5 h.  
In all of the cell lines, the conversion of 4-MUBA and resulting fluorescence increased as the 4-
MUBA concentration was increased.  The HT29-S and HCT116-S cells had elevated levels of 
activity compared to the SN-38-sensitive cells (Figure 14A and Figure 14B), suggesting CES 
activity may be related to drug resistance.  After compiling the data of four independent 
experiments, only the 0.2 mM concentration of 4-MUBA with HT29 and HT29-S showed any 
significant difference (p=0.0018; Figure 14A).  The lack of significance in this compilation could 
be attributed to the inter-experimental variation in fluorescence levels, because within individual 
experimental data sets there were significant differences (data not shown).  The compiled data 
are presented in Figure 14, and general trends can be seen between drug-resistant and drug-
sensitive cells within pairings.  Caco-2 cells exhibited high CES activity levels (Figure 14C); this 




Figure 14 Carboxylesterase activity in different colon cancer cells using 4-
methyumbelliferyl acetate (4-MUBA) 
HT29 and HT29-S (A), HCT116 and HCT116-S (B), and Caco-2 (C) cell lines were grown to 
90% confluence in 24-well plates, and were lysed with 100 µL of lysis buffer for 30 min at 4 °C.  
The lysate was centrifuged and 80 µL of supernatant was added to a 96-well plate prepared with 
six concentrations of 4-methyumbelliferyl acetate (4-MUBA).  Carboxylesterase enzyme activity 
was assessed through conversion of 4-MUBA into the fluorescent product 4-methyumbelliferone 
after a 2.5 h incubation at room temperature.  Excitation and emission spectra were 350 nm and 
450 nm respectively.  Relative fluorescence values were normalised within each experiment by 
subtracting the blank control values and adjusting the resulting values to cell counts for each cell 
line.  The data are means ± SEM.  All three panels show data from four independent 
experiments.  Data were analysed with a two-way ANOVA with Bonferroni multiple 
comparisons test (A, B) and Dunnett’s multiple comparisons test (C). *p=0.0018 shows a 
significant increase in carboxylesterase activity in HT29-S SN-38-resistant cells compared to 






3.3.2 p-nitrophenyl acetate (pNP) conversion in colon cancer cells  
In addition to the 4-MUBA assay, I wanted to compare with a different CES activity assay that 
used a colourimetric reaction.  In this assay, pNP was hydrolysed by CES and converted into the 
yellow product p-nitrophenolate.  pNP solutions were added to cells in 24-well plates and 
incubated for 2 hours.  Supernatant was removed at 20 min, 40 min, and 120 min time intervals 
and the absorbance measured.  
There was a drop in the absorbance values for HT29 and HCT116 cells after 120 min exposure 
to pNP, especially at elevated concentrations, as seen in Figure 7 and Figure 8.  I determined that 
it would be best to use the values obtained from the 40 min interval when collecting and 
combining data from the multiple experiments.  
While observing the absorbance values, the drug-resistant cells once again had elevated levels of 
CES activity, similar to the findings using 4-MUBA.  There was an increase in enzymatic 
conversion of pNP with the increasing concentrations of pNP across all cell lines, as indicated in 
Figure 15.  The HT29-S cells displayed elevated enzyme activity compared to the HT29 cells 
(Figure 15A).  The HCT116-S cells exhibited higher activity than HCT116 (Figure 15B).  At 
concentrations greater than 2 mM of pNP, there is a drop in the absorbance in HT29 and 
HCT116 cells.  This decrease is likely related to cytotoxic effects of the pNP at high 
concentrations (Figure 7).  The drug-resistant cells seem to be less affected by the presence of 
higher concentrations of pNP.  Caco-2 cells exposed to the 8 mM pNP concentration had 
significantly higher absorbance values after 40 min when compared to the lowest 0.25 mM 





Figure 15 Carboxylesterase activity in different colon cancer cells using p-nitrophenyl 
acetate (pNP) 
HT29 and HT29-S (A), HCT116 and HCT116-S (B), and Caco-2 (C) cell lines were grown to 
90% confluence in 24-well plates.  250 µL of p-nitrophenyl acetate (pNP) solutions at six 
concentrations were added to the wells.  Carboxylesterase activity was measured using pNP 
cleavage into p-nitrophenolate, a yellow-coloured product.  50 µL of supernatant was removed 
after 40 min, and absorbance was measured at 405 nm.  Absorbance values were normalised 
within each experiment by subtracting the blank control values and adjusting the resulting values 
to cell counts for each cell line.  The data are means ± SEM. All three panels show data compiled 
from four independent experiments.  Data were analysed with a two-way ANOVA with 
Bonferroni multiple comparisons test (A,B) and Dunnett’s multiple comparisons test (C). 
*p=0.0046 shows a significant increase in carboxylesterase activity in Caco-2 cells at a pNP 






3.4 Glutathione S-Transferase 
In addition to the enzymes that convert the CMFDA into a green fluorescent product, it was 
prudent to investigate GST, the enzyme that transforms CMFDA into its membrane-impermeable 
form.  The 1-chloro-2,4-dinitrobenzene (CDNB) used is conjugated with reduced glutathione 
(GSH) by the GST enzyme, generating a yellow-coloured product.  Elevated levels of GST 
activity were noted in the HT29-S cells when compared to HT29 (Figure 16A).  A general trend 
of increasing activity as the concentrations of CDNB and GSH were raised was also present.  
The HCT116 and HCT116-S cells showed no distinctive patterns across concentrations or 
between cell lines (Figure 16B).  The Caco-2 cells showed high levels of activity overall, 
indicating high enzymatic activity (Figure 16C).   
After compiling the data from four independent experiments, I noted that GST activity in the 
HCT116 and HCT116-S pair did not show the same patterns of drug-resistant cells having 
elevated enzyme activity compared to drug-sensitive cells as was previously described in the 
pilot experiment (Figure 13) and CES assays (Figure 14 and Figure 15).  In this instance there 
does not appear to be any clear trend to the data, even between the different concentrations of 
mixes.  This indicates that GST levels are not being affected by the drug resistance in the 








Figure 16 Glutathione S-transferase activity in different colon cancer cells using 1-chloro-
2,4-dinitrobenzene (CDNB) and reduced glutathione (GSH)  
HT29 and HT29-S (A), HCT116 and HCT116-S (B), and Caco-2 (C) cell lines were grown to 
90% confluence in 24-well plates, and were lysed with 100 µL of lysis buffer for 2 h at room 
temperature.  The lysates were separated using centrifugation and 20 µL of supernatant added to 
a 96-well plate. Six concentrations of CDNB and GSH, with ratios of 1:2, were added to the 
supernatant samples.  GST activity was measured using the resulting yellow coloured product 
from the conjugation of CDNB and GSH.  Absorbance was measured at 340 nm after 10 min 
reaction time at room temperature.  Absorbance values were normalised within each experiment 
by subtracting the blank control values and adjusting the resulting values to cell counts for each 
cell line.  The data are means ± SEM. All three graphs show data from four independent 
experiments, with no normalisation between experiments.  Data were analysed with a two-way 
ANOVA with Bonferroni multiple comparisons test (A,B) and Dunnett’s multiple comparisons 







In contrast, the HT29 and HT29-S pair exhibit a trend of increasing activity along the 
concentration levels, as well as elevated activity in the SN-38-resistant HT29-S cells compared 
to the HT29 cells (Figure 16A).  There was a decrease in enzyme activity when the concentration 
of CDNB was 4 mM; this decrease is likely indicative of cytotoxicity from the substrate mix at 
higher concentrations.  With the Caco-2 cells, the enzyme activity increased as the 
concentrations of substrate mix increased, until a 4 mM CDNB concentration was reached, at 
which point there was a decrease in activity (Figure 16C).  The differences along the 
concentration changes for Caco-2 were significant at the 0.5 mM, 1.0 mM, 2.0 mM, and 4.0 mM 










Chapter 4. Discussion 
4.1 Perspective  
Drug resistance in CRC coincides with altered behaviours of the cells, leading to more 
aggressive phenotypes.  Resistance is promoted through a variety of mechanisms including drug 
metabolism [26, 27].  In this project the initial intent was to investigate the cellular behaviours of 
drug-resistant colon cancer cells through the use of adhesion assays.  However, these 
experiments led to the novel observation that the SN-38-resistant cells were stained more 
vibrantly than the SN-38-sensitive cells.  To assess this observation, enzymes involved in both 
the metabolism of the cell stain, the metabolism of irinotecan, and drug resistance were assessed 











4.2 Cell Adhesion 
Little, if any, binding of HT29 cells to the FN coating was observed, although adhesion increased 
in the context of HepG2.  This increase in adhesion when comparing the HepG2 and fibronectin 
experiments is understandable because the ECM generated by the HepG2 cells has a wider 
variety of components to which the HT29 cells can adhere.  The HT29 cells are not limited to 
only using fibronectin receptors to attach to the ECM, and can employ other cell-ECM binding 
proteins. The drug-resistant HT29-S cells had elevated adhesion compared to the drug-sensitive 
HT29 cells in both the HepG2 and fibronectin experiments.   
HT29-S cells were often observed in clumps when adhered to the substratum.  This cell-to-cell 
adhesion is likely initiated prior to the addition of the cell suspension to coated wells.  This 
indicates that the drug-resistant cells have high levels of cell-to-cell adhesion in addition to 
adhesion to the ECM.  Elevated adhesion has been observed in other drug-resistant cancers as 
well [50]. The enhanced adhesion of these cells likely contributes to pro-survival signals, such as 
those initiated through integrin binding [46], and is a trait that would benefit these cells when 
they are mobile and traveling through the body.  Once the cells locate a favourable environment, 







During the adhesion experiments, I noticed that the drug-resistant HT29-S cells were brighter 
green when stained with the CMFDA than the drug-sensitive HT29 cells.  It was postulated that 
the difference in colouration and brightness could be an optical illusion, or it could be a genuine 
effect.  To pursue the latter idea further, cells were stained with CMFDA and the fluorescence 
observed (Figure 13).  Included in this experiment were HCT116 and HCT116-S cells to add 
another pair of drug-sensitive and drug-resistant cells to observe.  Caco-2 cells were used for 
colon cancer controls because the HepG2 cells were of liver origin.  The Caco-2 cells were also 
well differentiated, which provided some information on cells that have more mature enzyme 












4.3 5-chloromethylfluorescein diacetate (CMFDA) 
CMFDA is clear, colourless, and moves passively through cellular membranes.  It is used to 
fluorescently label live cells to observe their morphology and behaviour.  Once inside a cell, an 
acetate group is cleaved from the molecule by esterases, generating a green and fluorescent 
product (Figure 17).  GSTs conjugate GSH to CMFDA, which transforms CMFDA into a 
membrane-impermeable form (Figure 17).  CMFDA is simple to use, effective at staining, and 
does not harm the cells – it was selected as the stain of preference for these reasons.  
While performing adhesion experiments, HT29-S cells appeared to be more brightly coloured 
and fluorescing than the HT29 cells.  This was a repeated observation over the course of multiple 
experiments and was confirmed with colleagues.  This continual occurrence led to deeper 
investigation of the stain being used, its mechanism of action, and how these might relate to drug 
resistance.  It was suspected that the differential staining could be the result of altered CMFDA 












Figure 17 5-chloromethylfluorescein (CMFDA) conversion within a cell 
5-chloromethylfluorescein (CMFDA) is a clear, colourless compound that is membrane 
permeable and moves passively into cells.  Carboxylesterase (CES) converts CMFDA into a 
green and fluorescent product.  Glutathione S-transferase (GST) changes CMFDA from a 











The assessment of the question – is there a difference in CMFDA conversion between drug-
sensitive and drug-resistant cells – was accomplished through a simple pilot experiment 
involving the staining of six cell lines, two drug-resistant, their drug-sensitive counterparts, and 
two potential control cell lines.  The different intensities of fluorescence within the cells after 
treatment with CMFDA (Figure 13) indicate that the enzymes responsible for processing 
CMFDA into its green fluorescent product are present or active in different levels.  The more 
vibrant green indicates that the CMFDA is being converted more by CES, or there is greater 
retention of the product through increased GST activity.  
It was determined from the pilot experiment that the investigation of enzyme activity was worth 
pursuing, with a focus on CES because of its involvement in both irinotecan metabolism [63] and 
CMFDA conversion.  GST was the other enzyme selected because it is known to contribute to 













There is a noticeable difference in carboxylesterase (CES) activity between drug-resistant and 
drug-sensitive cells as indicated in the 4-MUBA (Figure 14) and pNP (Figure 15) experiments.  
This difference relates to the treatment of patients with irinotecan because CES1 and CES2 are 
prominently involved in the metabolism of irinotecan through the generation of the active 
metabolite SN-38.  Both extracellular metabolism at the cell surface and intracellular CES 
activity were assessed through these experiments.  The 4-MUBA assays account for both cell 
membrane bound and intracellular CES [54] because cell lysates were used, whereas the pNP 
assays would have given a better indication of the metabolism occurring at the cell surface 










4.4.2 4-methyumbelliferyl acetate (4-MUBA) conversion in SN-38-resistant colon cancer 
cells 
CES activity was measured using 4-MUBA cleavage into the fluorescent product 4-
methylumbelliferone.  In all five cell lines, there was an increase in enzyme activity as the 4-
MUBA concentration was increased (Figure 14).  The HT29-S and HCT116-S SN-38-resistant 
cells had elevated CES activity in comparison to their SN-38-sensitive counterparts.  This 
difference in activity was especially evident in the HT29-S cell line, and less so between the 
HCT116 and HCT116-S pair; these results follow the trends displayed in Figure 13.  The HT29-
S cells showed a roughly 3-fold increase in CMFDA conversion in the pilot experiment (Figure 
13) and a 2.5- to 2.7-fold increase across the concentrations in the compiled 4-MUBA 
experimental data (Figure 14).  The HCT116-S cells exhibited a 1.2-fold increase in the pilot 
experiment and the compiled data shows a range of roughly a 1.3- to 1.5-fold increase.  These 
values between the pilot experiment and CES activity assays are similar and indicate that CES 
activity is likely responsible for the majority of the difference in CMFDA staining within these 








4.4.3 p-nitrophenyl acetate (pNP) conversion in SN-38-resistant colon cancer cells  
Another assay used to measure CES activity was the colourimetric reaction involving pNP 
cleavage.  This assay hinges on CES cleaving an acetate group off of pNP to generate p-
nitrophenolate which is a yellow-coloured product. This reaction can also occur passively 
depending of the pH of the solution used; a pH of 7.0 was used in these experiments to prevent 
dissociation.  
The drug-resistant cell lines HT29-S and HCT116-S showed elevated levels of CES activity 
(Figure 15) and had values consistent with those from the 4-MUBA experiments and the 
CMFDA pilot experiment.  Interestingly, the drug-resistant cells were less affected by the 
presence of higher concentrations of pNP and did not experience as much cytotoxicity as the 
drug-sensitive cell lines.  This is indicative of a pro-survival mechanism that would prevent the 
cells from dying, although may not be directly linked to how the cells respond to pNP.  Rather, 
the drug-resistant cells may have alternative survival mechanisms employed, such as evasion of 
apoptosis or altered cell signalling, to prevent cell death [26].  There was no decrease in cell 







4.4.4 Importance of carboxylesterase activity in drug resistance   
How might these results contribute to our understanding of where the resistance of these cells is 
occurring?  In regards to the metabolism of irinotecan, elevated levels of CES in the intestinal 
cells would not play much of a role until second pass metabolism of the drug.  Irinotecan is 
administered intravenously and the primary metabolism of irinotecan would be occurring in the 
liver, which has high levels of CES [65].  The inactive metabolite of irinotecan, SN-38G, is 
secreted into the bile, which then enters the digestive tract.  Once in the tract, bacteria can cleave 
the SN-38G and reform the active metabolite SN-38 [22].  Although this processing of SN-38G 
would expose the CRC to the more potent metabolite of irinotecan, it does not explain the 
elevated CES in the CRC.  Elevated CES could convert any irinotecan that passes through the 
liver and eventually perfuses the CRC cells [66]. 
In the context of these in vitro assays, an alteration to the metabolic pathway elsewhere in the 
cells is more likely occurring.  The final product of CES conversion of irinotecan is already 
present, and so the enzymes become of little consequence in regards to conversion.  This would 
mean that the cells are likely responding to the SN-38 exposure in different ways.  It is possible 
that elevated levels of CES2 are in fact a secondary occurrence that could be the result of other 
treatments or additional aberrations that may be present within the cells, for example the 





4.4.5 Clinical relevance of carboxylesterase in colorectal cancer 
CES expression levels could play a role in clinical outcomes.  Elevated levels of CES2 in 
primary tumours may be indicative of more aggressive phenotype [68].  In the context of a 
patient, the CRC might have elevated CES levels as a result 5-FU being present within the 
treatment regimen.  5-FU can induce CES2 expression and protein levels within CRC [67], and 
given that patients with metastatic CRC are treated with a combination of irinotecan, 5-FU, and 
leucovorin [11], it may not be as simple as elevated CES2 being directly linked to tumour 
aggressiveness.  Although other forms of CES do exist within colon tissue, CES2 is the most 
abundant and active in regards to irinotecan hydrolysis [69].  In other cancers, such as pancreatic 
ductal adenocarcinoma, elevated CES2 expression corresponds with better survival when treated 
with irinotecan [70].  Given this information, it is possible that similar implications for survival 









4.5 Glutathione S-Transferase  
4.5.1 Overview 
GST has been implicated in drug resistance [71], and also converts CMFDA into a membrane-
impermeable form.  When this information is considered in conjunction with the results from the 
CMFDA conversion pilot experiment (Figure 13) it becomes apparent that GST may have some 
involvement in the drug resistance processes of the HT29-S and HCT116-S cells. This possibility 
was further tested by performing GST enzyme activity assays with five colon cancer cells lines – 
HT29, HT29-S, HCT116, HCT116-S, and Caco-2.   
Through these experiments, HCT116 and HCT116-S cells showed no distinctive patterns or 
trends between the cell lines or across the different substrate concentrations (Figure 16).  This 
likely indicates the GST is not playing a significant role in the drug-resistance mechanisms found 
within the HCT116-S cells.  These particular results also indicate that the differences in CMFDA 
conversion found within the HCT116 and HCT116-S cells (Figure 13) are not necessarily 
explained by an increase in GST activity.  The fluctuations in GST activity levels shown in 
Figure 16 may be explained by where in the cell cycle the majority of cells were at the time of 
the experiments. GST is known to be present at higher levels in growing cells, but lower levels in 
differentiating and maturing cells [59].  The Caco-2 cell line displayed a general trend of 
increasing activity as the concentrations of the substrates were increased.  This trend is indicative 
of a consistent level of functioning GST and substrate concentrations that do not fully saturate 




Of particular interest in the GST activity assays were the HT29 and HT29-S pair of cell lines.  
The HT29-S cells exhibited higher levels of GST activity than their drug-sensitive counterparts.  
GST is likely contributing to the drug resistance of the HT29-S cells, and in the very least aids in 
retention of the CMFDA stain.  The alteration in GST activity could possibly be explained by 
upregulation of the enzyme, however, further testing of gene expression and protein levels would 














4.5.2 Glutathione S-transferase involvement in cell survival  
The elevated levels of GST in SN-38-resistant HT29-S cells bring to question whether or not 
GST is directly involved in resistance mechanisms.  In all likelihood, GST does not directly 
contribute to the drug-resistance of these cells, but rather contributes to their ability to survive 
and thrive in conditions that would otherwise stimulate apoptosis.  In essence, elevated GST acts 
in a pro-survival manner.  This is quite likely given some findings that GST is not in and of itself 
causing drug resistance, but may be elevated in response to the exposure of SN-38 [60].  In order 
to confirm this, further assays would need to be performed involving the specific inhibition of 
GST to determine if cells become sensitised to the presence of SN-38.   
GSTP exists in a monomeric and dimeric state (Figure 18).  The dimeric state is primarily 
responsible for the conversion of substrates.  In the monomeric state, GSTP binds to JNK and 
functionally inhibits it [61], thereby preventing downstream signalling from JNK to Bax and 
other pro-apoptotic Bcl2-family proteins [62, 72, 73].  GSTP enables cell survival through the 
inhibition of pro-apoptotic signalling cascades initiated by JNK1.  By improving survival 
capabilities of the cells, the cells have a greater opportunity to acquire drug resistance through 
alternative mechanisms, such as those shown in Figure 4.  HT29-S cells had significantly higher 
levels of GST activity compared to HT29 cells (Figure 16).  These elevated levels of GST could 











Figure 18 GSTP1 inhibition of JNK1 
Dimeric GSTP1 acts primarily to conjugate reduced glutathione to xenobiotics to facilitate their 
removal, and does not bind to JNK1.  This allows JNK1 to signal the Bcl-2 family protein Bax 
which in turn promotes pro-apoptotic signaling.  Monomeric GSTP1 forms a protein complex 
with JNK1, which inhibits the signaling capacity of JNK1 and ensuing pro-apoptotic signal 









Additionally, JNK signalling pathways were recently highlighted as important apoptotic 
pathways in KRAS-mutant CRC cells, and these pathways can be induced through flavonoids 
such as quercetin [74].  Another example of overcoming drug resistance through JNK activation 
involved the addition of thymoquinone to irinotecan-resistant metastatic colon cancer cells [75].  
Although GSTP may be involved in cell survival and apoptotic pathways, there are many ways 
in which these pathways can be altered.  For example, in irinotecan-resistant cells, GSTP was 
elevated along with RhoA; when RhoA activity was reduced through the use of siRNA, the 
cancer cells regained some sensitivity to irinotecan [76].  This highlights the complexity of the 
involvement of apoptotic pathways and GSTP within them.  It is quite possible that even if one 
avenue of resistance is being treated, these cells may have alternative resistance mechanisms or 
pathways through which survival or apoptotic signals can be altered to improve the survivability 










4.5.3 Clinical considerations of glutathione S-transferase in cancer treatment 
In regards to clinical considerations of GST activity, the treatment of cells with GST inhibitors is 
a potential avenue for cancer treatment.  This would play into the dual nature of GST as a 
detoxifying enzyme, as well as its role in the reduction of pro-apoptotic signalling.  If GSTP 
activity were reduced this would, in theory, open up the pro-apoptotic signalling cascade 
mediated by JNK, and there would also be a reduction in GSTP mediated inactivation of 
xenobiotics and treatments.  Additionally, GSTP could be used to activate pro-drugs, which 
would then potentially target cancer cells with elevated levels of this enzyme [77].  In 
considering this route, it would be important to assess the balance of monomeric and dimeric 
GSTP because the ratio could potentially affect whether the GSTP protein is acting in an 
enzymatic conversion capacity or as a complexing protein to alter apoptotic signalling within the 
cells.  In addition to GST activity, genetic polymorphisms in GST genes may be of interest when 
considering clinical decisions.  For example, progression free survival outcomes for patients with 
metastatic CRC and treated with irinotecan were better in patients with a specific GSTP1 








4.6 Limitations of this Work 
One of the primary limitations inherent in this work is that it is in vitro.  There is the distinct 
possibility that this in vitro work will not fully transfer or have similar results in vivo, which is 
unfortunately a common issue that arises in biological studies and the path of bench to bedside. 
The inclusion of other cell lines – such as the SW480 and SW620 pair that originate from the 
same patient – may have shed light onto a more natural acquisition of resistance.  Primary patient 
isolates would have also provided an opportunity to improve and expand this work.   
Additionally, there is a lack of expression data within this study that could have been acquired 
through PCR-based experiments.  As well, western blots could be used to observe changes in the 
levels of the proteins of interest, namely CES2 and GSTP1.   These tests would add additional 
information regarding the gene expression and presence of a more mature enzyme profile, which 
would clarify where in the generation and processing the enzymes are being affected and 
potentially changed.  This merits further investigation. 
Within the experiments performed, the possibility exists that other enzymes may be capable of 
cleaving 4-MUBA and pNP.  This could have been addressed in part through information 
obtained from protein expression assays such as Western blots to assess the presence of other 
CES enzymes.  Spontaneous conversion of these substrates was addressed by using blanks 
exposed to the same conditions as the rest of the assay.  In hindsight, the CES activity assays are 
not as similar as could have been.  The pNP assay mainly addresses cell surface CES that 
converts the substrate, whereas the 4-MUBA assay addresses all CES, intracellular and 




4.7 Significance of this Work  
The work done in this study adds to existing literature regarding the implications of particular 
enzymes in drug resistance, specifically how CES and GSTP may be involved in resistance and 
pro-survival mechanisms.  This study highlights how enzymes may be involved in perpetuating 
drug resistance. Through this work, I was able to gain more insight into where in the chain of 
events drug resistance may be evolving within the HT29-S and HCT116-S cell lines developed 
by the Blay lab.  
Additionally, the complexity and interaction of treatments is brought to the forefront of 
discussion in regards to treating late stage and metastatic disease.  It is quite likely that although 
somewhat effective, combination therapies may also be eliciting synergistic or combating 
responses.  One example of this is highlighted by the variations that can be found in CES activity 
and its importance in the irinotecan metabolic pathway. This work also contributes to 
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A.1 Buffer and Reagent Recipes 
A.1.1 Phosphate Buffered Saline 
PBS (1 L, pH 7.4)  
137 mM NaCl  
2.7 mM KCl  
10.1 mM Na2HPO4  
1.8 mM KH2PO4  
1 L MilliQ H2O 
A.1.2 Paraformaldehyde 
3.7% PFA (pH 7.0, 10 mL prepared fresh on day of use)  
370 mg PFA dissolved into 9 ml MilliQ H2O. Use a hot plate set to low heat, stir gently with a 
magnetic stir bar  
Add 20 μL of 5 N NaOH to assist in solubilisation.  
Add 1 mL of 10X PBS.  
Adjust pH to 7.0 with 20 μL of 5 N HCl.  
Filter sterilize with a 0.22 μM pore filter. Keep at 37 °C prior to fixation. 
A.1.3 Lysis Buffer 
(pH 7.4, adjust pH before Triton X-100 addition, store at 4 °C)  
50 mM Tris-HCl  
2% Triton X-100  
5 mM EDTA  
0.25 mM NaCl 
A.1.4 Phosphate Buffer with Ca2+ Mg2+ 
KPBS Ca2+/Mg2+ (1 L, pH 7.4)  
90 mM KH2PO4  
40 mM KCl  
0.9 mM CaCl2-2H2O  
0.5 mM MgCl2-6H2O 
 
 
 
